Crossmark

C3 mutation-associated atypical hemolytic uremic syndrome with severe renal dysfunction and hypertensive emergency successfully treated with ravulizumab and sacubitril/valsartan: a case report

Crossref DOI link: https://doi.org/10.1186/s12882-026-04797-1

Published Online: 2026-02-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yanagidani, Hiroki

Maeoka, Yujiro

Yoshida, Maria

Ueda, Mayuko

Kumano, Mari

Takahashi, Akira

Okubo, Aiko

Kato, Noritoshi

Maruyama, Shoichi

Masaki, Takao
License Information

Text and Data Mining valid from 2026-02-12

Version of Record valid from 2026-03-18
More Information

Article History

Received: 22 November 2025

Accepted: 28 January 2026

First Online: 12 February 2026

Declarations

:

: This study was conducted according to the guidelines in the Declaration of Helsinki. Informed consent was obtained from the patient; the consent allowed his data to be stored, as required by Hiroshima University Hospital.

: Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below